

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/25807> holds various files of this Leiden University dissertation

**Author:** Verhaart, Ingrid

**Title:** Optimising antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy

**Issue Date:** 2014-05-20

# Optimising antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy

Proefschrift

ter verkrijging van

de graad van Doctor aan de Universiteit Leiden,

op gezag van Rector Magnificus prof.mr. C.J.J.M. Stolker,

volgens besluit van het College voor Promoties

te verdedigen op dinsdag 20 mei 2014

klokke 16.15 uur

door

Ingrid Esther Cynthia Verhaart

geboren te Eindhoven

in 1986

## **Promotiecommissie**

Promotor: Prof. Dr. G.J.B. van Ommen  
Co-promotor: Dr. A. Aartsma-Rus  
Overige leden: Prof. Dr. M.H. Breuning  
Prof. Dr. P. ten Dijke  
Prof. Dr. A. De Luca<sup>1</sup>  
Dr. W.M.H. Hoogaars<sup>2</sup>

<sup>1</sup> Department of Pharmacobiology, University of Bari, Bari, Italy

<sup>2</sup> Laboratory for Myology, MOVE Research Institute Amsterdam, Faculty of Human Movement Sciences, VU Medical Center, Amsterdam, the Netherlands

Cover: designed by Elisabeth Salmin (kleine hex)

Printed by: Uitgeverij BOXPress, 's-Hertogenbosch

ISBN 978-90-8891-859-9

A trade edition based on this thesis is in preparation (LAP LAMBERT Academic Publishing, ISBN 978-3-659-28683-4)

The studies described in this thesis have been performed at the department of Human Genetics, Leiden University Medical Center, Leiden. The work was financially supported by a grant from the Prinses Beatrix Spierfonds, the Netherlands (grant W.OR09-12).

Copyright© 2014 I.E.C. Verhaart. All rights reserved. No part of this thesis may be reproduced or transmitted in any form or by any means, without prior permission in writing of the author.



# Table of Contents

<b>1.</b>	<b>General introduction</b>	<b>7</b>
1.1	Duchenne and Becker Muscular Dystrophy	9
1.2	<i>DMD</i> gene and dystrophin protein	10
1.2.1	Genetic defects in DMD and BMD	10
1.2.2	Dystrophin protein	12
1.2.3	Animal models for DMD	14
1.3	Antisense oligonucleotide-mediated exon skipping	19
1.3.1	Backbone chemistries	21
1.3.2	AON design and targets	22
1.3.3	Antisense-mediated exon skipping <i>in vitro</i>	22
1.3.4	Antisense-mediated exon skipping <i>in vivo</i> in animal models	25
1.3.4.1	AONs in murine models for DMD	25
1.3.4.2	AONs in other animal models	29
1.3.5	AONs in clinical trials	30
1.3.5.1	Local treatment with AONs	30
1.3.5.2	Systemic treatment with AONs	30
1.3.6	Improvement of AON delivery and efficiency	36
1.4	Other approaches targeting the underlying genetic defect	38
1.4.1	Stop codon readthrough	38
1.4.2	<i>Trans</i> -splicing	40
1.4.3	Gene replacement	41
1.4.4	Cell therapy	44
1.4.5	Genome editing	45
	<b>Outline of this thesis</b>	<b>47</b>
<b>2.</b>	<b>Targeting the secondary defects in Duchenne muscular dystrophy</b>	<b>49</b>
2.1	Utrophin upregulation	54
2.2	Corticosteroids and other anti-inflammatory compounds	54
2.3	NO-cGMP signalling pathway	57
2.4	Anti-oxidants	59
2.5	TNF- $\alpha$ and the IKK-NF- $\kappa$ B signalling pathway	60
2.6	Nutritional intervention and dietary-derived compounds	62
2.7	The TGF- $\beta$ superfamily	64
2.7.1	Myostatin inhibition	67
2.7.2	Targeting TGF- $\beta$ signalling	70
2.7.3	BMP antagonists	72
2.8	The Renin-Angiotensin System	73
2.9	Insulin-like growth factor 1 stimulation	76
2.10	Anabolic agents	77
2.11	HDAC-inhibitors	79
2.12	Improvement of calcium homeostasis	80
2.13	Matrix metalloproteinases	83
2.14	Autophagy	83
2.15	Treatment of cardiomyopathy	84
2.16	Summary	86

3.	<b>Dose-dependent pharmacokinetic profiles of 2'-<i>O</i>-methyl phosphorothioate antisense oligonucleotides in <i>mdx</i> mice</b>	<b>89</b>
4.	<b>The dynamics of compound, transcript and protein effects after treatment with 2OMePS antisense oligonucleotides in <i>mdx</i> mice</b>	<b>107</b>
5.	<b>The effect of 6-thioguanine on alternative splicing and antisense-mediated exon skipping treatment for Duchenne muscular dystrophy</b>	<b>121</b>
6.	<b>Prednisolone treatment does not interfere with 2'-<i>O</i>-methyl phosphorothioate antisense-mediated exon skipping in DMD</b>	<b>133</b>
7.	<b>The effect of losartan <i>in vitro</i> and <i>in vivo</i> on muscle signalling and function and antisense oligonucleotide-mediated exon skipping</b>	<b>151</b>
8.	<b>General discussion</b>	<b>163</b>
	<b>References</b>	<b>168</b>
	<b>Appendix</b>	<b>199</b>
	Summary	200
	Samenvatting voor niet-ingewijden	202
	List of Abbreviations	206
	Curriculum Vitae	209
	List of Publications	211
	Dankwoord	213

